CVS Gains in Pharmacy & Consumer Wellness Despite Reimbursement Woes
CVS Health's Pharmacy & Consumer Wellness unit posts double-digit revenue gains despite ongoing reimbursement headwinds.
BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth
bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.
Nuclear Medicine Market is expected to generate a revenue of USD 12.99 Billion by 2032, Globally, at 9.30% CAGR: Verified Market Research®
Lewes, Delaware, Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- The Global Nuclear Medicine Market Size is projected to grow at a CAGR of 9.30% from 2026 to 2032, according to a new report published by Verified Market Research®.
5 Dividend Growth Stocks to Boost Your Portfolio
Five dividend growth stocks, AGCO, VRT, TEL, CAH and WWD, stand out for their steady payouts, strong fundamentals and long-term upside potential.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal ( CAH ) is an Incredible Growth Stock: 3 Reasons Why
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
All You Need to Know About Cardinal ( CAH ) Rating Upgrade to Buy
Cardinal (CAH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy Cardinal Health ( CAH ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health to Acquire Solaris Health for Urology Expansion
CAH is set to buy Solaris Health for $2.4B, boosting urology presence with 750+ providers and expanding Specialty Alliance reach.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
After Plunging 9.1% in 4 Weeks, Here's Why the Trend Might Reverse for Cardinal ( CAH )
The heavy selling pressure might have exhausted for Cardinal (CAH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Brokers Suggest Investing in Cardinal ( CAH ) : Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Cardinal (CAH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Company News for Aug 13, 2025
Companies In The News Are: CAH, SE, CRCL, ONON.
Why Cardinal Health Stock Was Tumbling on Tuesday
The healthcare conglomerate handily beat on the bottom line in its latest reported quarter, but that's not what the market was paying attention to.
Cardinal Health ( CAH ) Tops Q4 Earnings Estimates
Cardinal (CAH) delivered earnings and revenue surprises of +2.46% and -0.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Decoding Cardinal Health's Options Activity: What's the Big Picture? - Cardinal Health ( NYSE:CAH )
Whales with a lot of money to spend have taken a noticeably bullish stance on Cardinal Health. Looking at options history for Cardinal Health CAH we detected 25 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish ...
Zacks Industry Outlook Highlights McKesson, Cardinal Health, West Pharmaceutical Services and The Cooper Companies
Despite tariff headwinds and softer elective procedure demand, McKesson, Cardinal Health, West Pharmaceutical Services, and The Cooper Companies are positioned for steady gains in the dental supplies space.
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls
Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Why Is Cardinal Health Stock Falling Tuesday? - Cardinal Health ( NYSE:CAH )
Q4 EPS $2.08 beat $2.04 estimate; sales $60.16 billion missed $60.89 billion consensus Cardinal Health to buy Solaris Health for $1.9 billion, closing by the end of 2025. This simple system has nailed 1,000+ post-earnings winners. Get in before Q3 trades take off → Cardinal Health Inc.
EYE Stock Gains on Q2 Earnings and Revenue Beat, '25 View Up
National Vision tops on Q2 earnings and revenues, boosts 2025 guidance after strong sales and margin expansion.
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte Q2 earnings and revenues beat estimates, fueled by Decipher and Afirma growth, sending shares up over 15%.
Is Invesco S&P 500 Equal Weight Health Care ETF ( RSPH ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Cardinal Health Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Cardinal Health ( NYSE:CAH )
Cardinal Health, Inc. CAH will release earnings results for the fourth quarter before the opening bell on Tuesday, Aug. 12. Analysts expect the health care company to report quarterly earnings at $2.03 per share, up from $1.84 per share in the year-ago period.
How To Earn $500 A Month From Cardinal Health Stock Ahead Of Q4 Earnings - Cardinal Health ( NYSE:CAH )
A more conservative goal of $100 monthly dividend income would require 587 shares of Cardinal Health. An investor would need to own $462,313 worth of Cardinal Health to generate a monthly dividend income of $500. The next 100%+ earnings move could hit this month. See how to find it live on ...
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
TNDM Stock Falls on Q2 Earnings Miss, Revenues Beat, Gross Margin Up
Tandem Diabetes posts record Q2 sales and higher margins, but earnings miss sends shares tumbling 20%.
Has Adaptive Biotechnologies ( ADPT ) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Cardinal Health (CAH) have performed compared to their sector so far this year.
Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings?
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal fourth-quarter revenues despite an uncertain macroeconomic environment.
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
Zimmer Biomet gains as Q2 earnings and revenues top estimates. full-year EPS guidance raised on strong segment growth.
What Analyst Projections for Key Metrics Reveal About Cardinal ( CAH ) Q4 Earnings
Beyond analysts' top-and-bottom-line estimates for Cardinal (CAH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View
STERIS posts 15% EPS growth and raises FY26 revenue outlook, with all segments showing solid year-over-year gains.
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Can Sustained Product Demand Drive BDX Stock Before Q3 Earnings?
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
Can Solventum Sustain Growth Amid Tariff Headwinds in Q2 Earnings?
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
Henry Schein Stock Falls on Q2 Earnings Miss, Revenues Top
HSIC slides after Q2 EPS misses estimates by 6.8%. Revenues beat with 3.2% growth and strength across key segments.
Will GLP-1 Demand Drive MCK's Top Line This Earnings Season?
MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
XRAY's Imaging strength and SureSmile growth might have lifted Q2 performance, but Byte's drag and macro pressures likely clouded the top-line momentum.
Zimmer Biomet to Report Q2 Earnings: Here's What to Expect
ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.
Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?
HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.
SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up
SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down
Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.
CVS Stock Up on Q2 Earnings & Revenue Beat, '25 EPS View Raised
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
ALGN Stock Falls on Q2 Earnings and Revenue Miss, Margins Down
Align Technology tumbles 34.2% after Q2 earnings and revenues miss estimates as Clear Aligner sales drop and margins tighten further.
Should Value Investors Buy Cardinal Health ( CAH ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Will SYK's Q2 Earnings Reflect Strong Growth Despite Tariff Overhang?
Stryker's second-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs and tariffs are likely to have continued to hurt margins.
